This information, together with the docking analysis of the FPR1/RI-3 complex may provide sufficient information for the design of peptide derivatives labeled with therapeutic radioisotopes, to elicit additional cytotoxic activity against cancer cells. This evidence concerns the gene FPR1 and cancer.